Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
BusinessWire - Wed Jan 06, 1:00AM CST
Regulatory News:
Transgene Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Oct 21, 10:45AM CDT
Regulatory News:
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
BusinessWire - Wed Aug 19, 10:45AM CDT
Regulatory News:
Transgene Reports First Quarter 2015 Financial Results
BusinessWire - Wed Apr 22, 11:00AM CDT
Regulatory News:
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 45.26 (+0.45), NWBO: 0.45 (-0.01), ZIOP: 5.12 (+0.12), PCYC: 261.25 (+1.70), CVM: 0.48 (+0.01), PFE: 35.44 (+0.29), CLDX: 4.66 (+0.15), IMGN: 3.11 (+0.25), BMY: 63.28 (-12.04), RIGL: 3.08 (+0.16), INO: 9.85 (+0.21), KITE: 58.59 (+0.20), LH: 140.76 (+0.67), ABBV: 66.54 (+0.44), PBYI: 48.29 (+0.70)